With more than 130 Sessions, the EANM Annual Congress is the most valuable Nuclear Medicine Meeting worldwide. Each year, more than 5,500 participants have the possibility to network, socialize and discuss the newest trends and findings in the field of Nuclear Medicine. The EANM has approximately 2,100 abstracts annually from all over Europe
and overseas. 130 exhibiting companies, covering an area of 3,000 sqm present their newest technologies.
Members of the Q BioMed advisory group and technology partners will be meeting with industry colleagues, collaborators and manufactures of materials required for the scale up and production of Q BioMeds recently licensed, FDA approved, SR89 drug. This licensed radiopharmaceutical agent is indicated for the treatment of pain associated with metastatic bone cancer. SR89 provides long lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases, it has been proven to provide a long-term effect resulting in non–narcotic cancer pain relief and enhanced quality of life.
There are approximately 300,000 new cases of bone metastases in patients with breast and lung cancer per year in the U.S. alone. Approximately 80% of patients using SR89 have reported experiencing a substantial decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics, such as morphine.
Q BioMed CEO, Denis Corin
said, “Key raw materials required for the manufacturing of the drug are sourced from Europe
and this meeting provides an ideal opportunity to meet with all the relevant suppliers and stakeholders. These relationships and the agreements that result from these meetings are an important milestone as we begin roll out of the manufacturing process.”Connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.